TRML vs. TCRX, AURA, SLDB, REPL, OCGN, TNYA, MGTX, JSPR, BDTX, and CCCC
Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include TScan Therapeutics (TCRX), Aura Biosciences (AURA), Solid Biosciences (SLDB), Replimune Group (REPL), Ocugen (OCGN), Tenaya Therapeutics (TNYA), MeiraGTx (MGTX), Jasper Therapeutics (JSPR), Black Diamond Therapeutics (BDTX), and C4 Therapeutics (CCCC). These companies are all part of the "biological products, except diagnostic" industry.
TScan Therapeutics (NASDAQ:TCRX) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Tourmaline Bio has a net margin of 0.00% compared to Tourmaline Bio's net margin of -653.50%. TScan Therapeutics' return on equity of -25.13% beat Tourmaline Bio's return on equity.
TScan Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 36.05%. Tourmaline Bio has a consensus price target of $61.80, indicating a potential upside of 309.00%. Given TScan Therapeutics' higher possible upside, analysts clearly believe Tourmaline Bio is more favorable than TScan Therapeutics.
TScan Therapeutics received 13 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 74.19% of users gave TScan Therapeutics an outperform vote.
TScan Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500.
Tourmaline Bio has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, TScan Therapeutics had 11 more articles in the media than Tourmaline Bio. MarketBeat recorded 31 mentions for TScan Therapeutics and 20 mentions for Tourmaline Bio. TScan Therapeutics' average media sentiment score of 1.15 beat Tourmaline Bio's score of 0.04 indicating that Tourmaline Bio is being referred to more favorably in the news media.
82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 2.8% of TScan Therapeutics shares are held by insiders. Comparatively, 11.0% of Tourmaline Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Tourmaline Bio beats TScan Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Tourmaline Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tourmaline Bio Competitors List
Related Companies and Tools
